Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Find the Insider facts of Compelling Systems administration: Building Associations for Progress - 26 Agreeable Earphones To Wear
- 3Watch interstellar comet 3I/ATLAS make its closest approach to Earth in free livestream on Dec. 18
- 4How to watch 2026 Golden Globe winners like 'One Battle After Another,' 'Adolescence' and 'The Pitt'
- 5This star-forming galaxy is blowing out powerful winds topping 2 million mph
- NASA's Artemis 2 pilot Victor Glover listens to 'Whitey on the Moon' every Monday. This is why.
- Kendall Jenner addresses long-standing rumor about her sexuality
- Every year, she thanks the trooper for the arrest that led to her sobriety
- AfD faction in western Germany ousts councilman for firebrand speech
- Pick Your Top Method for starting the Morning
- Easter Island quarry reveals how Polynesians made enigmatic stone statues
- Carrefour becomes first European retailer to offer shopping on ChatGPT
- Help Your Business with Master Web based Promoting Arrangements
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
